SCHEDULE 13G: Samuel D. Tweardy Discloses 10.1% Passive Stake in TVARDI THERAPEUTICS, INC.

Samuel D. Tweardy has reported a 10.1% beneficial ownership stake in TVARDI THERAPEUTICS, INC., holding 946,974 shares through various trusts.

Summary

• Samuel D. Tweardy has filed a Schedule 13G with the SEC, disclosing beneficial ownership of 946,974 shares of Common Stock in TVARDI THERAPEUTICS, INC.
• This ownership represents 10.1% of the Issuer's outstanding common stock.
• The percentage is calculated based on 9,355,542 shares of TVARDI THERAPEUTICS, INC.'s common stock outstanding as of April 15, 2025.
• The shares are held through three separate trusts: Benjamin John Tweardy 2020 Gift Trust, Daniel James Tweardy 2020 Gift Trust, and Samuel David Tweardy 2020 Gift Trust, with 315,658 shares directly held in each trust.
• Samuel D. Tweardy, acting as the trustee for these trusts, holds sole voting and sole dispositive power over all 946,974 shares.
• The filing indicates a passive investment intent, as per Rule 13d-1(c), with a certification that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a substantial 10.1% passive ownership stake by Samuel D. Tweardy, which can be viewed as a positive signal of confidence in the company, although it does not provide operational or financial performance details.

Positives

• A significant individual investor, Samuel D. Tweardy, has taken a substantial 10.1% stake in TVARDI THERAPEUTICS, INC., which could be interpreted as a signal of confidence in the company's long-term prospects.
• The investment is structured through gift trusts, potentially indicating a long-term holding strategy for the beneficial owners.

Risks

• The filing explicitly states that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, which mitigates immediate risks related to activist investor actions or hostile takeovers.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from TVARDI THERAPEUTICS, INC. regarding its future operations or financial performance.

Industry Context

This filing is a standard disclosure of a significant passive ownership stake by an individual. While it does not provide specific industry trends, a 10.1% stake in a therapeutics company by an individual investor is a notable event in the biotechnology and pharmaceutical sectors, where capital structure and significant shareholders are closely monitored.

Related Party Transactions

• The beneficial ownership is held through three gift trusts (Benjamin John Tweardy 2020 Gift Trust, Daniel James Tweardy 2020 Gift Trust, Samuel David Tweardy 2020 Gift Trust), for which Samuel D. Tweardy serves as trustee. This structure represents a related party holding arrangement.

Stakeholder Impact

• Shareholders: Provides increased transparency regarding a significant shareholder. The presence of a substantial passive investor might be viewed positively by the market.

Key Dates

Keywords

TVARDI THERAPEUTICS, Samuel D. Tweardy, Schedule 13G, beneficial ownership, common stock, passive investment, equity stake, SEC filing, biotechnology, pharmaceuticals